Related Experiment Videos
Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies
A C Franke1, D Jung, T M Ellis
1Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University School of Medicine, Maywood, IL 60153, USA.
Insights
Monoclonal antibodies targeting CD30 (cluster A and C) can block CD30 ligand binding, unlike cluster B antibodies. This finding aids in understanding CD30 signaling and developing diagnostic assays.
Area of Science:
- Immunology
- Molecular Biology
- Cell Signaling
Background:
- CD30 and CD30 ligand (CD30L) are key regulators of lymphocyte function within the TNF superfamily.
- Monoclonal antibodies (MAbs) against CD30 are classified into three serologic clusters based on mutual inhibition.
- The precise epitopes targeted by these MAbs and their impact on CD30L binding remain unclear.
Purpose of the Study:
- To investigate the relationship between CD30 epitope clusters and the CD30L binding domain.
- To determine which anti-CD30 MAbs can inhibit CD30L interaction with CD30.
- To assess the utility of these findings for functional studies and assay development.
Main Methods:
- Utilized a soluble CD30L/CD8alpha chimeric protein to test MAb inhibition of CD30L binding.
- Assessed binding inhibition on the CD30+ Karpas 299 cell line.
- Evaluated anti-CD30L MAbs for their ability to inhibit CD30/CD30L interaction.
Main Results:
- Anti-CD30 MAbs from cluster Group A (e.g., Ber-H2, Ber-H8) and Group C (e.g., HeFi-1, M44) effectively blocked CD30L binding.
- Anti-CD30 MAbs from cluster Group B (e.g., M67, Ki-1) did not inhibit CD30L binding.
- The anti-CD30L MAb M81 also completely inhibited CD30/CD30L interaction.
- Limited correlation was observed between MAb epitope specificity and their capacity to trigger CD30 signaling.
Conclusions:
- CD30 epitope mapping reveals distinct functional consequences for different MAb clusters.
- Cluster A and C antibodies are suitable for blocking CD30L binding, impacting lymphocyte regulation studies.
- Findings support the rational design of functional assays and therapeutic strategies targeting the CD30/CD30L pathway.
Abstract:
CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation. Several monoclonal antibodies (MAbs) have been developed against CD30 and, based on mutual inhibition assays, are grouped into three nonoverlapping serologic clusters. However, the relationship between the epitopes recognized by the antibodies comprising each cluster and the binding domain for CD30L is not known. Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line. CD30L binding by CD30 is blocked by MAb that recognize epitopes belonging to cluster Group A (like Ber-H2, Ber-H8, and HRS-4) as well as cluster Group C (like HeFi-1 and M44). Cluster Group B antibodies, including M67 and Ki-1, do not affect CD30L binding to CD30. The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling. Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction. This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.